Literature DB >> 3813511

Penicillins, cephalosporins, and tetracyclines in treatment of hamsters with fatal leptospirosis.

A D Alexander, P L Rule.   

Abstract

A predictable 6- to 7-day course of a fatal Leptospira interrogans serovar bataviae infection in experimentally infected mature 110- to 150-g hamsters was used to evaluate the therapeutic efficacy of conventionally used and newer antibiotics. Active drugs were ampicillin, bacampicillin, cyclacillin, piperacillin, mezlocillin, doxycycline, chlortetracycline, cefotaxime, and moxalactam. Cephalexin, cefadroxil, cefamandole, and cefoperazone showed little or no activity in preliminary studies. In delayed treatment studies, all nine active drugs prevented death of hamsters even when treatment was delayed until 1 to 2.5 days before expected time of death. Leptospires in kidneys of surviving animals could be demonstrated in one or more hamsters treated with doxycycline, chlortetracycline, cyclacillin, and piperacillin, but in none of the animals treated with ampicillin, bacampicillin, mezlocillin, cefotaxime, and moxalactam. The potential usefulness of newer penicillins and cephalosporins, as well as ampicillin, chlortetracycline, and doxycycline, for treatment of severe leptospirosis is reported.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3813511      PMCID: PMC180603          DOI: 10.1128/AAC.30.6.835

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Tylosin therapy in experimental leptospirosis.

Authors:  G E WOOD; A D ALEXANDER
Journal:  Antibiot Chemother (Northfield)       Date:  1961-09

2.  [Antibiotic therapy of leptospiroses].

Authors:  O GSELL
Journal:  Schweiz Med Wochenschr       Date:  1959-04-18

3.  Pathogenic leptospiras isolated from Malaysian surface waters.

Authors:  A D Alexander; L B Evans; M F Baker; H J Baker; D Ellison; M Marriapan
Journal:  Appl Microbiol       Date:  1975-01

4.  Evaluation of antibiotic therapy in human leptospirosis.

Authors:  H E HALL; J A HIGHTOWER; R DIAZ RIVERA; R J BYRNE; J E SMADEL; T E WOODWARD
Journal:  Ann Intern Med       Date:  1951-11       Impact factor: 25.391

5.  In vitro susceptibilities of five Leptospira strains to 16 antimicrobial agents.

Authors:  S Oie; K Hironaga; A Koshiro; H Konishi; Z Yoshii
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

6.  [In vitro bacteriostatic effect of current antibiotics on pathogenic Leptospirae].

Authors:  M Füzi
Journal:  Orv Hetil       Date:  1982-12-19       Impact factor: 0.540

7.  Treatment of human leptospira infections with semicillin (ampicillin) or with amoxil (amoxycillin).

Authors:  D Münnich; M Lakatos
Journal:  Chemotherapy       Date:  1976       Impact factor: 2.544

8.  [Clinical experience with romicil (oleandomycin), a new antibiotic].

Authors:  R HEGGLIN; G KEISER; W SIEGENTHALER
Journal:  Dtsch Med Wochenschr       Date:  1956-12-21       Impact factor: 0.628

9.  An efficacy trial of doxycycline chemoprophylaxis against leptospirosis.

Authors:  E T Takafuji; J W Kirkpatrick; R N Miller; J J Karwacki; P W Kelley; M R Gray; K M McNeill; H L Timboe; R E Kane; J L Sanchez
Journal:  N Engl J Med       Date:  1984-02-23       Impact factor: 91.245

10.  [A case of Leptospira hebdomadis infection treated with piperacillin (author's transl)].

Authors:  Y Kanazawa
Journal:  Jpn J Antibiot       Date:  1979-09
View more
  17 in total

Review 1.  Leptospirosis.

Authors:  P N Levett
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

2.  In vitro susceptibilities of seven Leptospira species to traditional and newer antibiotics.

Authors:  Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  In vitro and in vivo activity of first generation cephalosporins against Leptospira.

Authors:  Brande M Harris; Peter J Blatz; Mary K Hinkle; Suzanne McCall; Miriam L Beckius; Katrin Mende; Janelle L Robertson; Matthew E Griffith; Clinton K Murray; Duane R Hospenthal
Journal:  Am J Trop Med Hyg       Date:  2011-11       Impact factor: 2.345

4.  In vitro sensitivity and resistance of 46 Leptospira strains isolated from rats in the Philippines to 14 antimicrobial agents.

Authors:  Antara Chakraborty; Satoshi Miyahara; Sharon Y A M Villanueva; Nina G Gloriani; Shin-Ichi Yoshida
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

5.  Efficacy of macrolides and telithromycin against leptospirosis in a hamster model.

Authors:  James E Moon; Michael W Ellis; Michael C Ellis; Matthew E Griffith; Joshua S Hawley; Robert G Rivard; Suzanne McCall; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

6.  Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.

Authors:  Roseanne A Ressner; Matthew E Griffith; Miriam L Beckius; Guillermo Pimentel; R Scott Miller; Katrin Mende; Susan L Fraser; Renee L Galloway; Duane R Hospenthal; Clinton K Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

7.  Cefotaxime for therapy of acute leptospirosis.

Authors:  I Thangkhiew
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

8.  Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

Authors:  R K Straubinger; B A Summers; Y F Chang; M J Appel
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

9.  Determination of susceptibilities of 26 Leptospira sp. serovars to 24 antimicrobial agents by a broth microdilution technique.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Broth microdilution susceptibility testing for Leptospira spp.

Authors:  Clinton K Murray; Duane R Hospenthal
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.